Results 191 to 200 of about 12,503,861 (249)
ABSTRACT Self‐determination has been assessed as an internal psychological construct. External factors may also affect self‐determination, but opportunities to make choices and decisions remain understudied. We developed and evaluated the AASPIRE‐Choices and Decisions Scale (AASPIRE‐CDS), a new measure of autistic adults' opportunities to make choices ...
So Yoon Kim +14 more
wiley +1 more source
ABSTRACT Autism exhibits substantial phenotypic heterogeneity, yet age‐dependent variation in phenotypic profiles and onset timing remains poorly understood. We aimed to characterize stage‐specific phenotypes and temporal onset patterns of autism using longitudinal electronic health records (EHRs).
Fangyi Chen +9 more
wiley +1 more source
ABSTRACT Cognitive tests that reflect the complexity of real‐world social interactions are essential for autism spectrum disorder (ASD)‐related clinical assessment and research. This study developed and adapted a Japanese version of the Reading the Mind in Films (RMF) test, which assesses mind‐reading ability through dynamic, multisensory, and context ...
Sayaka Kawakami +3 more
wiley +1 more source
ABSTRACT Extreme/pathological demand avoidance (EDA) is a behavioral profile characterized by the avoidance of everyday demands, with significant impact on the individuals and those around them. Little is understood regarding the correlates and drivers of EDA; understanding these better may lead to targeted interventions and support strategies.
Oliver Lack +6 more
wiley +1 more source
Patient‐reported outcomes (PROs) are essential for assessing clinical benefit and tolerability from the patient's perspective. In oncology trials, PRO data analysis often involves responder and time‐to‐event analyses, which depend on predefined thresholds to determine clinically meaningful change.
Anna Margarete Maria Thurner +5 more
wiley +1 more source
Zuranolone: A case study in (regulatory) rush to judgement?
Abstract Sage, in collaboration with Biogen, submitted a new drug approval for zuranolone for postpartum depression (PPD) and major depressive disorder (MDD) in December 2022. In August 2023, the US Food and Drug Administration granted approval for PPD but denied approval for MDD.
Lisa Cosgrove +4 more
wiley +1 more source

